Expression of RUNX3 in skin cancers

Clicks: 330
ID: 267894
2011
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #5 of 183 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 183 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Background. Expression of Runt‐related transcription factor 3 (RUNX3) is reduced in a large number of cancers. However, a few studies have reported higher expression of RUNX3 in several cancers, including basal cell carcinoma (BCC). In light of this, we explored the expression of RUNX3 in skin cancers generally, to determine whether it acts as an oncogene or a tumour‐suppressor gene in skin tumours. Aim. To investigate the expression of RUNX3 in normal skin and malignant skin tumours. Methods. RUNX3 expression was evaluated by western blotting in 24 specimens, comprising 6 malignant melanoma (MM), 6 squamous cell carcinoma (SCC), 6 BCC and 6 normal skin specimens. Immunohistochemical staining was carried out to analyse RUNX3 expression in 16 MM, 16 SCC and 16 BCC specimens. To identify where the protein was expressed, the cytoplasmic and nuclear protein expression of RUNX3 in skin cancer tissues was determined. A cell‐proliferation study was performed on an MM line (G361) by small interfering (si)RNA transfection. Results. The western blotting experiments showed that RUNX3 was not expressed in normal skin tissues, but it was overexpressed in all MM and SCC samples, and in five of the six BCC samples. Using immunochemistry, RUNX3 was found to be overexpressed in all cancer tissues analysed. Subcellular fraction analysis revealed that RUNX3 was expressed in the nuclei but not the cytoplasm of all the skin cancer tissues analysed, and RUNX3 silencing by siRNA in G361 cells resulted in a decrease in proliferation. Conclusions. Based on these results, we suggest that RUNX3 has an oncogenic potential and does not act as a tumour suppressor in skin cancers.
Reference Key
cho2011clinicalexpression Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors J. H. Lee,J.-K. Pyon,D. W. Kim,S. H. Lee,H. S. Nam,S. G. Kang,C. H. Kim,Y. J. Lee,J. S. Chun,M. K. Cho;J. H. Lee;J.-K. Pyon;D. W. Kim;S. H. Lee;H. S. Nam;S. G. Kang;C. H. Kim;Y. J. Lee;J. S. Chun;M. K. Cho;
Journal clinical and experimental dermatology
Year 2011
DOI
10.1111/j.1365-2230.2011.04069.x
URL
https://sciprofiles.com/publication/view/ef753d6e2fef6e999a62316558dcddd8
Keywords
protein transcription factor tumour runx3 malignant tissues bcc skin cancers overexpressed

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.